» Articles » PMID: 33061353

Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2020 Oct 16
PMID 33061353
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Gender differences in the incidence, susceptibility and severity of many obstructive airway diseases (OADs) have been well recognized. However, gender differences in the inhaled pharmacotherapy profile are not well characterized.

Methods: We conducted a retrospective cohort study to investigate gender differences in new-users of inhaled corticosteroids (ICS), short-or long-acting beta-agonist (SABA or LABA), ICS/LABA, short-or long-acting muscarinic antagonist (SAMA or LAMA) among patients with asthma, COPD or asthma-COPD overlap (ACO). We used Clinical Practice Research Datalink to identify OAD patients, 18 years and older, who were new-users (1-year washout period) from 01-January-1998 to 31-July-2018. Multivariable logistic regression was used to examine gender differences in each of the inhaled pharmacotherapies after controlling for potential confounders.

Results: A total of 242,079 new-users (asthma: 84.93%; COPD: 10.19%; ACO: 4.88%) of inhaled pharmacotherapies were identified. The multivariable analyses showed that males with COPD were more likely to be a new user of a LABA (odds ratio [OR] 1.29; 95% confidence interval [CI], 1.12-1.49), LAMA (OR 1.21; 95% CI 1.10-1.33), SAMA (OR 1.11; 95% CI 1.01-1.21) and less likely to be a new user of a SABA (OR 0.84; 95% CI, 0.80-0.89) compared to females. Similar patterns were also observed for patients with ACO; males were more likely to be prescribed with LABA (OR 1.26; 95% CI 1.03-1.55), LAMA (OR 1.28; 95% CI 1.11-1.48), SAMA (OR 1.28; 95% CI 1.11-1.48), and less likely to be a new user of a SABA (OR 0.89; 95% CI, 0.82-0.96). Also, males with asthma were more likely to be a new-user of ICS/LABA (OR 1.15; 95% CI, 1.08-1.23) and less likely to start an ICS (OR 0.97; 95% CI, 0.95-0.99) in comparison with females.

Conclusion: Our study showed significant gender differences in new-users of inhaled pharmacotherapies among OAD patients. Adjusting for proxies of disease severity, calendar year, smoking and socioeconomic status did not change the association by gender.

Citing Articles

Trends in initial pharmacological COPD treatment in primary care (2010-2021): a population-based study using the PHARMO Data Network.

Rodrigues G, Antao J, Deng Q, Baak B, Marques A, Franssen F Respir Res. 2024; 25(1):447.

PMID: 39736696 PMC: 11687194. DOI: 10.1186/s12931-024-03073-w.


Sex differences in airway disease: estrogen and airway surface liquid dynamics.

Harvey B, McElvaney N Biol Sex Differ. 2024; 15(1):56.

PMID: 39026347 PMC: 11264786. DOI: 10.1186/s13293-024-00633-z.


Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care - a United States cohort study.

Baldomero A, Kunisaki K, Wendt C, Henning-Smith C, Hagedorn H, Bangerter A Lancet Reg Health Am. 2023; 26:100597.

PMID: 37766800 PMC: 10520452. DOI: 10.1016/j.lana.2023.100597.


Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada.

Amegadzie J, Lee T, Sadatsafavi M, Lynd L, Sin D, Johnson K CMAJ. 2023; 195(35):E1172-E1179.

PMID: 37696554 PMC: 10495179. DOI: 10.1503/cmaj.221051.


Identification of Sex-Specific Genetic Polymorphisms Associated with Asthma in Middle-Aged and Older Canadian Adults: An Analysis of CLSA Data.

Odimba U, Senthilselvan A, Farrell J, Gao Z J Asthma Allergy. 2023; 16:553-566.

PMID: 37197194 PMC: 10184860. DOI: 10.2147/JAA.S404670.


References
1.
Quint J, Mullerova H, DiSantostefano R, Forbes H, Eaton S, Hurst J . Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014; 4(7):e005540. PMC: 4120321. DOI: 10.1136/bmjopen-2014-005540. View

2.
Cadeddu C, Capizzi S, Colombo D, Nica M, de Belvis A . Literature review of gender differences in respiratory conditions: a focus on asthma and Chronic Obstructive Pulmonary Disease (COPD). Ig Sanita Pubbl. 2017; 72(5):481-504. View

3.
Theorell-Haglow J, Olafsdottir I, Benediktsdottir B, Gislason T, Lindberg E, Janson C . Sex differences in reported and objectively measured sleep in COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11:151-60. PMC: 4734736. DOI: 10.2147/COPD.S94268. View

4.
McDonald L, Schultze A, Carroll R, Ramagopalan S . Performing studies using the UK Clinical Practice Research Datalink: to link or not to link?. Eur J Epidemiol. 2018; 33(6):601-605. DOI: 10.1007/s10654-018-0389-5. View

5.
Papaioannou A, Bania E, Alexopoulos E, Mitsiki E, Malli F, Gourgoulianis K . Sex discrepancies in COPD patients and burden of the disease in females: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study). Int J Chron Obstruct Pulmon Dis. 2014; 9:203-13. PMC: 3933352. DOI: 10.2147/COPD.S52500. View